Animal Pharm is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By


Daniel Willis

Set Alert for Articles By Daniel Willis

Latest From Daniel Willis

Invoxia seeks animal health expertise for development of GPS pet tracker

French telecommunications specialist Invoxia is taking its expertise in the human GPS space into the companion animal market.

Companion Animals Equipment & Technology

Amlan names new sales director for Asia Pacific region

Amlan International has appointed Clare Mari Torralba to the role of regional sales director for the Asia Pacific region.

Asia Pacific People

Roslin study to investigate influenza A species spread

A new study by The Roslin Institute aims to identify genes that are vital in reducing infection of influenza A virus in pigs and chickens.

Avian influenza Research

Veramaris research reveals importance of omega-3 to salmon industry

Research from Veramaris has revealed a strong connection between omega-3 eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) content in salmon, and increased salmon consumption frequency among US consumers.

Research Aquaculture

Swedish pet product firm establishes Spanish subsidiary

Malmo-based Swedencare has opened a sales and marketing subsidiary based in Barcelona. 

Operations Markets

Ark accelerates second canine therapeutic development, eyes potential spin-out

California-based Ark Animal Health began work on establishing a companion animal therapeutics portfolio in 2014. After five years, the company is readying the launch of its resiniferatoxin candidate. Animal Pharm analyst Daniel Willis spoke to Ark president Alexis Nahama at the recent Animal Health Investment Europe forum in London about the company's future plans. 

R&D Companion Animals
See All